Recently the clinical application of bone metabolic markers has achieved significant progress and the measurements of these indices give us a better under standing of the pathogenesis of osteoporosis.Bone metabolic markers were adapted to select drug treatment for osteoporosis and to evaluate drug efficacy.Therefore,the proper application and assessment of bone metabolicmarkers in clinical practice is very important.To achieve these aims,the committee on the guidelines for the use of biochemical markers of bone turnover in osteoporosis authorized by the Japan Osteoporosis Society has summarized recent progress in bone markers and proposed the proper utilization of bone markers.Although the use of bone metabolic markers now has an important role in the daily management of osteoporosis,their use in Japan is still insufficient because of insurance coverage limitations.Since the Japan Osteoporosis Society first created the 2001 guidelines,new bone metabolic markers have been introduced into clinical practice.The availability of new osteoporosis treatments that promote bone formation has changed the clinical application of bone metabolic markers in current practice.Therefore,revisions to the current clinical practice are needed which led to the proposal to create these new 2012 guidelines.%近年来,骨代谢标志物临床应用已取得了显著的进展,这些指标的测量,让我们对骨质疏松症的发病机制有一个更好的了解.骨代谢标志物用于选择骨质疏松治疗药物和评价药物疗效.因此,合理应用和评价骨代谢标志物在临床实践中是非常重要的.为了实现这些目标,由日本骨质疏松症学会授权的骨质疏松骨代谢指标应用指南制定委员会,总结骨代谢指标最新研究进展,并提出了骨代谢指标的合理应用.虽然现在骨代谢指标,在骨质疏松症的日常管理工作中具有重要的作用,但由于医保范围的限制,在日本的应用仍不普遍.自日本骨质疏松症学会制定了2001年指南,新的骨代谢指标已列入临床实践.新的促进骨形成的骨质疏松症治疗方法,改变了骨代谢指标在临床实践中的应用.因此,需要调整目前的临床应用方案,提出制定新的2012年指南的建议.
展开▼
